Haploidentical Bone Marrow Transplant

Introduction

If you or someone in your family has been advised to consider a haploidentical bone marrow transplant, you are probably holding many questions at once. What does “half-matched” mean? Is this as good as a fully matched transplant? How long will recovery take? What will daily life look like during and after treatment?

This article walks through the haploidentical bone marrow transplant process from start to finish — what it is, who it is used for, how donors are chosen, what happens during conditioning and infusion, how engraftment works, the risks involved, and what recovery and long-term life look like. It is written for patients and families who are already in active conversation with a transplant team and want a clear, plain-language understanding of what lies ahead.

Haploidentical transplant is one of the most important advances in blood and marrow transplantation in recent decades. Before its development, many patients who lacked a fully matched donor had limited options. Today, because almost everyone has a parent, child, or sibling who is at least a half match, this approach has made transplant accessible to far more people.

What Is a Haploidentical Bone Marrow Transplant?

A bone marrow transplant — also called a stem cell transplant or hematopoietic cell transplant (HCT) — replaces unhealthy blood-forming cells in the bone marrow with healthy stem cells from a donor. The new stem cells settle in the bone marrow and start producing healthy red blood cells, white blood cells, and platelets.

An allogeneic transplant is one in which the stem cells come from another person (the donor), rather than from the patient themselves. For an allogeneic transplant to work safely, the donor and patient need to be matched on a set of markers called human leukocyte antigens (HLA). HLA markers are inherited and help the immune system tell the body’s own cells apart from foreign cells.

A fully matched donor shares all key HLA markers with the patient. A haploidentical donor shares exactly half. The word “haploidentical” literally means “half-identical.”

Because every child inherits half of their HLA markers from each parent, the following relatives are almost always at least a half match:

• A biological parent
• A biological child
• A biological full or half sibling (who may share more or less than half, depending on inheritance)
• Sometimes cousins, aunts, uncles, or nieces and nephews

For many years, doctors hesitated to use half-matched donors because the mismatch could trigger severe immune complications, including life-threatening graft-versus-host disease (GVHD) and graft rejection. Newer approaches — especially the use of a chemotherapy drug called post-transplant cyclophosphamide (PTCy), pioneered at Johns Hopkins and now used widely around the world — have changed this picture significantly. PTCy is given a few days after the donor stem cells are infused. It quietens the immune cells that would otherwise attack the patient’s tissues, while sparing the cells that help the transplant succeed.

With these modern protocols, haploidentical transplant outcomes in many settings are now broadly comparable to fully matched unrelated donor transplants, although the exact picture depends on the underlying disease, the patient’s overall health, and other factors.

Who Is Haploidentical Transplant For?

Haploidentical bone marrow transplant is considered for patients who need an allogeneic transplant but do not have a fully matched donor available — either among siblings or in the international unrelated donor registries.

It may also be considered when:

• The disease is progressing quickly and waiting for an unrelated donor search is not safe
• An unrelated donor search is unlikely to succeed (this is more common for patients from ethnic groups underrepresented in donor registries)
• A suitable family donor is readily available and can be evaluated quickly
• Previous unrelated donor transplant has failed and a different donor source is needed

Conditions Treated

Haploidentical transplant is used for a wide range of serious blood and marrow disorders, including:

• Acute leukaemias — acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), particularly in high-risk or relapsed disease
• Chronic leukaemias with high-risk features, including some cases of chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL)
• Myelodysplastic syndromes (MDS)
• Myeloproliferative neoplasms, including myelofibrosis
• Hodgkin and non-Hodgkin lymphomas, particularly relapsed or refractory disease
• Aplastic anaemia and other inherited or acquired bone marrow failure syndromes
• Severe haemoglobinopathies, including transfusion-dependent thalassaemia and sickle cell disease (most often in children and young adults)
• Primary immunodeficiencies and certain inherited metabolic disorders

The decision to recommend transplant — and whether to pursue a haploidentical donor specifically — rests with the treating haematology and transplant team, based on the disease type, stage, prior treatment response, and the patient’s overall fitness.

Alternatives to Consider

Haploidentical transplant is one of several donor options. Before proceeding, the transplant team usually reviews the full picture:

• Matched sibling donor transplant — if a fully matched brother or sister is available, this is often the first preference
• Matched unrelated donor (MUD) transplant — using a fully matched volunteer donor identified through international registries
• Umbilical cord blood transplant — using stem cells collected from donated umbilical cord blood, which tolerates more HLA mismatch than adult cells
• Autologous transplant — using the patient’s own stem cells, applicable in certain lymphomas and myeloma but not in most leukaemias
• Continuing non-transplant therapy — such as chemotherapy, targeted therapy, or immunotherapy, when transplant is not appropriate or not yet needed

The choice between these options depends on donor availability, disease urgency, the patient’s age and fitness, prior treatments, and the experience of the transplant centre. Many centres now consider a well-matched haploidentical family donor and a matched unrelated donor as broadly comparable options for adult patients, although practice varies.

The Haploidentical Transplant Process: Step by Step

1. Pre-Transplant Evaluation

Before transplant, a detailed assessment is carried out to confirm that the patient is fit enough to go through the procedure and that the chosen donor is suitable.

Patient evaluation usually includes:

• Detailed blood tests and a bone marrow biopsy to assess current disease status
• Genetic and molecular tests on the disease, where relevant
• Heart function tests (echocardiogram, ECG)
• Lung function tests
• Liver and kidney function tests
• Screening for infections such as hepatitis B and C, HIV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and tuberculosis
• Dental review to identify and treat sources of infection
• Nutritional assessment
• Psychological assessment and counselling for the patient and family
• Discussion of fertility preservation options, where age and disease timing allow

2. Donor Selection

HLA testing is performed on all potentially suitable family members. Because every biological parent and child is automatically a half match, and roughly half of siblings will be at least a half match, most patients have one or more potential donors.

When more than one half-matched relative is available, the team considers several factors to choose the best donor, including:

• Donor age and general health
• Donor blood group compared to the patient’s
• CMV status
• For female donors, the number of previous pregnancies
• Specific HLA features and natural killer (NK) cell compatibility
• Donor weight (which affects how many stem cells can be collected)

The donor undergoes their own medical evaluation, including blood tests, infection screening, heart and lung checks, and a conversation about the donation process and its risks. Donor safety is a central concern at every transplant centre.

3. Disease Control Before Transplant

In most leukaemias and lymphomas, the goal before transplant is to bring the disease into the best possible remission. This is because transplant works best when the amount of disease in the body is low.

This pre-transplant phase may involve:

• Chemotherapy regimens specific to the disease
• Targeted therapies, such as tyrosine kinase inhibitors or FLT3 inhibitors
• Immunotherapy, including monoclonal antibodies or CAR T-cell therapy in selected cases
• Radiation therapy in some lymphomas

For non-malignant conditions such as aplastic anaemia or thalassaemia, the focus is more on supportive care — transfusions, iron management, and infection prevention — rather than disease reduction.

4. Central Venous Catheter Placement

A central venous catheter (often a tunnelled line such as a Hickman line, or sometimes a PICC line) is placed under local or general anaesthesia. This soft tube sits in a large vein near the heart and stays in place for many months. It is used to deliver chemotherapy, stem cells, blood products, antibiotics, nutrition, and to draw blood for tests without repeated needle sticks.

5. Conditioning Therapy

Conditioning is the chemotherapy — and sometimes radiation — given in the days before stem cell infusion. It has two purposes:

• To destroy any remaining disease cells
• To suppress the patient’s immune system enough that it does not reject the incoming donor cells

There are two broad types of conditioning:

• Myeloablative conditioning (MAC) — high-dose chemotherapy with or without total body irradiation. It wipes out the bone marrow completely. Used most often in younger, fitter patients.
• Reduced-intensity conditioning (RIC) — lower-dose chemotherapy that suppresses but does not fully destroy the marrow. Better tolerated by older patients or those with other health conditions.

Conditioning typically lasts five to seven days. Side effects begin during this phase and may include nausea, mouth sores (mucositis), diarrhoea, fatigue, and hair loss. Strong anti-sickness medication and supportive care are part of the routine.

6. Stem Cell Infusion (Transplant Day)

The day the donor stem cells are infused is referred to as day zero. Days before are counted in negative numbers (day −1, day −2, and so on); days after are counted in positive numbers.

The stem cells themselves are collected from the donor either from peripheral blood (after the donor receives injections of a growth factor that pushes stem cells from the marrow into the bloodstream) or directly from the bone marrow under anaesthesia. Peripheral blood collection is more common for adult donors.

The infusion itself feels much like a blood transfusion. The donor cells are given through the central line over a few hours. Patients are awake and monitored closely. Some patients notice a strange taste or smell, mild flushing, or a brief change in heart rate. Major reactions are uncommon.

7. Post-Transplant Cyclophosphamide and Immune Modulation

What makes haploidentical transplant distinct from other allogeneic transplants is the use of post-transplant cyclophosphamide (PTCy), typically given on days +3 and +4 after the infusion. Cyclophosphamide is a chemotherapy drug, but in this setting it is used to selectively destroy the donor immune cells that would otherwise attack the patient. The stem cells that produce the new marrow are largely spared.

Alongside PTCy, additional immune-suppressing medications — commonly tacrolimus or ciclosporin, and mycophenolate mofetil — are usually started a few days after transplant and continued for several months. These help prevent GVHD and allow the new immune system to settle in gradually.

8. Engraftment

Engraftment is the point at which the donor stem cells begin producing new blood cells in measurable numbers. For neutrophils (a type of white blood cell), this is typically defined as a count rising above a threshold for three consecutive days.

Engraftment usually happens between days +15 and +30 after a haploidentical transplant, though it can be a little slower than with some other transplant types. During the waiting period — sometimes called the “aplastic phase” — the patient has very low blood counts and is at high risk of infection and bleeding.

Day-to-day care during this period includes:

• Isolation in a protected room, often with filtered air
• Frequent blood tests, sometimes daily
• Blood and platelet transfusions as needed
• Antibiotics, antifungals, and antiviral medications to prevent infection
• Mouth care for mucositis
• Intravenous nutrition if eating is too difficult
• Close monitoring for fever, breathing difficulty, or any sign of infection

Most patients stay in hospital for around four to six weeks, although this varies considerably.

Risks and Complications

Haploidentical transplant is a major treatment with significant risks. Understanding these risks helps patients and families recognise problems early and make informed decisions during recovery.

Infection

Until the new immune system rebuilds, the risk of infection is high. Bacterial, viral, and fungal infections are all possible. Reactivation of viruses already in the body — particularly cytomegalovirus (CMV), Epstein-Barr virus (EBV), and BK virus — is closely monitored through regular blood tests after transplant.

Graft-Versus-Host Disease (GVHD)

GVHD happens when donor immune cells recognise the patient’s tissues as foreign and attack them. It comes in two forms:

• Acute GVHD — typically appears within the first 100 days. It most often affects the skin (rash), gut (diarrhoea, nausea), and liver (abnormal liver tests).
• Chronic GVHD — develops later and can affect many organs, including skin, eyes, mouth, lungs, joints, and the gastrointestinal tract. It can be mild or severe and sometimes lasts for years.

With the use of post-transplant cyclophosphamide, the rate and severity of GVHD after haploidentical transplant has fallen substantially. Many patients still experience some GVHD, but most cases are manageable with adjustments in immunosuppressive medication. Mild chronic GVHD is sometimes associated with a stronger graft-versus-leukaemia effect, which can help prevent relapse.

Graft Failure

Occasionally, the donor cells do not engraft, or engraft and then fail. This is uncommon but serious, and may require a second transplant or other intervention.

Organ Toxicity

High-dose chemotherapy and the strain of transplant can affect the liver, kidneys, heart, and lungs. One specific complication is sinusoidal obstruction syndrome (SOS), also called veno-occlusive disease, in which small blood vessels in the liver become blocked.

Disease Relapse

For patients transplanted for cancer, the disease can come back after transplant. The risk depends heavily on the type of disease, how much disease was present before transplant, and other factors. The first one to two years after transplant carry the highest relapse risk, although later relapse is also possible.

Late Effects

Some complications appear months or years after transplant. These can include:

• Hormonal changes (thyroid problems, reduced fertility, early menopause)
• Cataracts
• Bone thinning (osteoporosis)
• Heart and lung problems
• Secondary cancers
• Persistent fatigue

Early Recovery: Hospital and the First 100 Days

After discharge from hospital — often four to six weeks after the transplant — most patients stay close to the transplant centre for regular outpatient visits. Blood tests, fluid replacement, transfusions, and infusions are often still needed. Energy levels are usually low, and most patients sleep more than usual and eat less than usual.

During this period, the immune system is still very weak. Daily life involves careful infection prevention: avoiding crowds, wearing a mask in public, hand hygiene, food safety, and avoiding contact with anyone who is unwell.

Intermediate Recovery: Months Three to Twelve

From about day +100 onward, many patients begin to regain stamina and slowly return to gentle daily activities. Immunosuppressive medications are gradually reduced as the new immune system shows signs of settling. Vaccinations — which need to be redone after transplant because the old immunity is lost — are usually started during this phase, following a structured schedule.

Common experiences during this phase include:

• Fluctuating energy levels
• Hair regrowth, sometimes with changes in colour or texture
• Taste changes that gradually settle
• Mood changes, including periods of low mood or anxiety
• Gradual return to work or school in some cases, often part-time

Late Recovery: One Year and Beyond

By around one year, many patients are off most immunosuppressive medications, immunity has improved substantially, and life resembles a near-normal pattern. Full immune recovery, however, can take two years or longer. Long-term follow-up continues to monitor for relapse, late effects, and chronic GVHD.

The pace of recovery varies widely. Some patients return to work and most activities within a year. Others, especially those who develop chronic GVHD or other complications, may take longer. Most transplant teams give individual estimates based on the patient’s own course.

Life After Haploidentical Transplant

Life after a haploidentical transplant brings real opportunities and some long-term considerations.

Follow-Up and Monitoring

Regular clinic visits continue for years. Typical follow-up includes:

• Blood tests to track blood counts, organ function, and signs of relapse
• Bone marrow tests at intervals, especially in the first one to two years
• Chimerism testing — a blood test that shows how much of the patient’s blood cells come from the donor
• Monitoring for viral reactivation
• Screening for chronic GVHD
• Screening for late effects, including thyroid and hormonal function, bone health, heart and lung function, and skin checks
• Re-vaccination on a structured schedule

Diet and Hygiene

For several months after transplant, transplant teams generally advise:

• Eating freshly prepared, thoroughly cooked food
• Avoiding raw or undercooked meat, fish, and eggs
• Avoiding unpasteurised dairy and unwashed fruit and vegetables
• Drinking only safe, treated water
• Strict hand hygiene
• Avoiding gardening, soil, and bird or animal droppings during early recovery
• Wearing a mask in crowded indoor spaces

These restrictions ease as immune function improves and immunosuppressive medications are reduced.

Physical Activity

Gentle activity — walking, light stretching, breathing exercises — is usually encouraged early on. As strength returns, structured exercise rebuilds stamina and muscle. Many transplant centres involve physiotherapists in recovery planning.

Emotional and Mental Health

Transplant is an intense experience for the patient and the whole family. It is common to experience a mix of relief, anxiety, low mood, post-traumatic stress symptoms, or fear of relapse during recovery. These responses are not a sign of weakness; they are recognised parts of the transplant journey. Psychological support, counselling, and patient support groups can help, and transplant teams usually have these available.

Fertility and Family Planning

Conditioning therapy often affects fertility. The impact depends on the conditioning regimen used, age, and other factors. Where time and the medical situation allow, options for fertility preservation (such as sperm banking or egg or embryo freezing) may be discussed before transplant. After transplant, fertility-related questions are best discussed with the transplant team and, where relevant, a reproductive specialist.

Returning to Work, School, and Travel

Returning to work or school usually happens gradually, often starting around six months to a year after transplant. Travel, especially long-distance or international travel, is typically discussed with the transplant team and depends on immune recovery, vaccination status, and the destination.

Haploidentical Transplant in Children

Paediatric haploidentical transplant is used for conditions including:

• Acute leukaemias, particularly high-risk or relapsed disease
• Severe aplastic anaemia where matched donor options are not available
• Transfusion-dependent thalassaemia
• Sickle cell disease in selected high-risk cases
• Primary immunodeficiency disorders, including severe combined immunodeficiency (SCID)
• Certain inherited metabolic conditions

Children often tolerate transplant differently from adults. Engraftment may be faster, and many children recover stamina more quickly than adult patients. However, children face particular considerations:

• Growth and development — conditioning therapy can affect growth, puberty, and hormonal development. Long-term endocrine follow-up is important.
• Schooling — children miss substantial school time during and after transplant. Many transplant centres work with families on home schooling, gradual return-to-school plans, and educational support.
• Vaccination — children lose their childhood vaccinations after transplant and need re-vaccination on a paediatric post-transplant schedule.
• Family impact — one parent often becomes the primary caregiver during a prolonged hospital stay. Siblings may feel the strain. Paediatric transplant programmes typically offer family-centred psychological support.
• The donating parent — when a parent donates to their child, the emotional weight on the donor parent can be significant. Counselling and support for the donor parent is an important part of good paediatric transplant care.

Long-term outcomes after paediatric haploidentical transplant continue to improve, and for some conditions — such as severe thalassaemia or sickle cell disease — the goal is full cure with a near-normal life expectancy.

Frequently Asked Questions

Is a haploidentical transplant as effective as a fully matched transplant?

For many conditions and in many published studies, outcomes after haploidentical transplant with modern protocols are broadly comparable to those after matched unrelated donor transplant. Individual results depend on the specific disease, disease stage, patient fitness, and other factors. The transplant team can give a personalised estimate.

How is the best half-matched donor chosen when several relatives are available?

Transplant teams consider donor age, general health, blood group, CMV status, certain HLA features, NK cell compatibility, and (for female donors) pregnancy history. Younger, healthy donors are often preferred. The final choice is a clinical judgement based on the full picture.

Is donating safe for my relative?

Donating stem cells is generally safe for healthy donors, but it is not risk-free. Peripheral blood stem cell donation involves a few days of growth-factor injections, which can cause bone aches and fatigue, and a collection procedure through a vein. Bone marrow donation involves a short anaesthetic and some soreness afterwards. Donors are carefully screened to confirm they are fit enough to donate, and donor safety is a primary concern.

How long will I be in hospital?

Most patients stay in hospital for approximately four to six weeks during the transplant itself, although this varies. After discharge, patients typically remain close to the transplant centre for regular outpatient visits for at least the first 100 days.

How long until I feel normal again?

There is no single answer. Many patients begin to feel substantially better between six months and a year after transplant. Full immune recovery often takes two years or more. Some patients have a smooth course; others experience complications such as GVHD that affect the timeline.

Will I need to take medications for the rest of my life?

Most patients take immunosuppressive medications for several months to a year or so after transplant, then gradually stop them. Some patients with chronic GVHD or other complications need longer or even indefinite immunosuppression. Other medications — such as those for bone health, hormone replacement, or specific late effects — depend on individual circumstances.

Can the disease come back after transplant?

For patients transplanted for cancer, relapse is possible. The risk is highest in the first one to two years and depends on the disease, its stage, and how well it was controlled before transplant. Regular monitoring is designed to catch relapse early, when more options remain available.

Will my new immune system be different from my old one?

Yes. After engraftment, the patient’s blood and immune cells come from the donor. This is why blood group can change after transplant if the donor has a different blood group, and why childhood vaccinations need to be repeated — the old immunity is replaced by a new system that has not yet learned what to recognise.

Are there limits on contact with my family during recovery?

During the inpatient and early outpatient phases, visitors are usually limited and must be free of any signs of illness. Close family members are typically the primary visitors. As immunity recovers, restrictions ease. Each transplant centre has its own policies, and these are explained in detail before admission.

Conclusion

Haploidentical bone marrow transplant has changed what is possible for patients with serious blood and marrow disorders who do not have a fully matched donor. With the use of post-transplant cyclophosphamide and other modern protocols, outcomes have improved substantially, and most patients now have at least one suitable half-matched family donor available.

The process is long and demanding — weeks of conditioning and inpatient care, months of close outpatient follow-up, and a year or more of gradual recovery. Risks are real, particularly infection, graft-versus-host disease, and the possibility of relapse. But for many patients and families, the chance of long-term disease control or cure — and a return to a meaningful daily life — makes this path worth the journey.

Understanding what to expect at each phase — donor selection, conditioning, infusion, engraftment, early recovery, and long-term follow-up — helps patients and families partner effectively with their transplant team and approach each stage with realistic expectations and confidence.